NCT06093087

Brief Summary

This study is a multicenter, prospective, double-blind, randomized controlled trial using a parallel two-arm design to investigate whether the postoperative 6-month quality of life, vertebral stability, complication of patients with osteoporotic vertebral compression fractures (Kummell's disease) are better with the use of stent screw internal fixation and percutaneous bone cement reconstruction technique compared to patients undergoing traditional percutaneous balloon kyphoplasty (BKP) for vertebral augmentation

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
70

participants targeted

Target at P75+ for phase_1

Timeline
16mo left

Started Jan 2024

Typical duration for phase_1

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress64%
Jan 2024Sep 2027

First Submitted

Initial submission to the registry

October 19, 2023

Completed
4 days until next milestone

First Posted

Study publicly available on registry

October 23, 2023

Completed
2 months until next milestone

Study Start

First participant enrolled

January 1, 2024

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2027

Expected
8 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2027

Last Updated

October 23, 2023

Status Verified

October 1, 2023

Enrollment Period

3 years

First QC Date

October 19, 2023

Last Update Submit

October 19, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • ODI score

    Each patients were asked to complete the Oswestry Disability Index questionnaire postoperatively during follow up

    ODI score measured 1,3,6 months post surgery during follow up

Secondary Outcomes (4)

  • CT imaging indicators related to vertebral body stability

    all variables were measured 1,3,6 months post surgery during follow up

  • SF36 score

    measured 1,3,6 months post surgery during follow up

  • VAS score

    measured 1,3,6 months post surgery during follow up

  • EQ-5D score

    measured 1,3,6 months post surgery during follow up

Study Arms (2)

SAIF

EXPERIMENTAL

patients will be treated with kyphoplasty surgery combined with pedicular screw-assisted internal fixation for vertebral augmentation

Procedure: SAIF

BKP

ACTIVE COMPARATOR

patients will be treated with balloon kyphoplasty surgery for vertebral augmentation

Procedure: BKP

Interventions

SAIFPROCEDURE

The patient was placed in a prone position under general anesthesia. Using a C-arm X-ray machine and a positioning plate for navigation, the target position on the vertebral body was located one the surface of the body. The puncture needle core was withdrawn after puncturing, and a guide needle was inserted. After removing the puncture needle sleeve, a hollow bone cement screw was screwed into the anterior column of the vertebral body through the guide needle. Subsequently, bone cement was injected into the appropriate position through the bone cement screw to restore the vertebral height

SAIF
BKPPROCEDURE

The patient was placed in a prone position after general anesthesia. Using a C-arm X-ray machine and a positioning plate for guidance, the target position on the vertebral body was located from the surface of the body. A puncture needle sleeve was inserted into the vertebral body. A PKP balloon was then inserted to perform vertebral restoration. After removing the balloon, an appropriate amount of bone cement was injected to ensure even distribution within the vertebral body. Vertebral height augmentation and restoration will then be achieved.

BKP

Eligibility Criteria

Age60 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age 60 or above, gender not specified.
  • Must have one to three vertebral segments with vertebral compression fracture (VCF) located between T5 and L5, attributed to underlying primary or secondary osteoporosis rather than cancer.
  • All VCFs must exhibit the following radiographic changes: according to Genant's criteria, acute (≤4 months) decrease in anterior, middle, or posterior vertebral height by at least one grade (20-25% reduction in vertebral height, 10-20% reduction in vertebral area) compared to previous X-ray, CT, or MRI results.
  • All VCFs for treatment must occur within four months or less.
  • All VCFs for treatment must be technically feasible and clinically suitable for BKP or SAIF surgery.
  • Pre-treatment back pain NRS score must be ≥ 7 and ineffective with conservative (non-surgical) treatment.
  • Pre-treatment Oswestry Disability Index must be ≥ 30 (on a scale of 0-100).
  • Patient's life expectancy must be ≥ 12 months.
  • Must declare willingness to participate in all post-operative follow-ups.
  • Must be capable of understanding the risks and benefits of the study and willing to provide written informed consent.

You may not qualify if:

  • Vertebral morphology or fracture morphology unsuitable for balloon kyphoplasty. VCF caused by high-energy trauma.
  • Asymptomatic VCF or vertebral bodies amenable to prophylactic treatment.
  • VCF at the same site associated with primary bone tumors.
  • Back pain caused by reasons other than acute fractures. VCF with an estimated fracture time of more than 4 months, based on clinical assessment (radiological evidence and patient history).
  • VCF associated with secondary radiculopathy or neurological compromise.
  • VCF requiring spinal surgery other than BKP or SAIF.
  • Spinal cord compression or vertebral canal injury requiring decompression surgery.
  • Combined clinical conditions unsuitable for surgery or affecting subsequent long-term data collection or follow-up.
  • Allergy to any component during the surgical procedure (e.g., bone cement, contrast agents).
  • Concurrent participation in another clinical study.
  • Pregnancy during the study or planning to become pregnant.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Central Study Contacts

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 19, 2023

First Posted

October 23, 2023

Study Start

January 1, 2024

Primary Completion (Estimated)

January 1, 2027

Study Completion (Estimated)

September 1, 2027

Last Updated

October 23, 2023

Record last verified: 2023-10